The Unapproved QUAD Cocktail: A Closer Look at its Composition QUAD is a compounded sublingual dose product marketed by MEDVi…
Read More
Medvi’s QUAD Erectile Dysfunction Cocktail Raises Significant Safety Concerns Amidst Regulatory Scrutiny and Questionable Marketing Practices
The burgeoning telehealth industry, lauded for its potential to democratize healthcare access, is facing intensified scrutiny as companies push the…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
In the wake of The New York Times’ April 2 profile, which painted MEDVi CEO Matthew Gallagher as a "vibe-coded…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
QUAD is marketed by MEDVi as a sublingual, four-drug cocktail for erectile dysfunction, combining three well-known PDE5 inhibitors—sildenafil, tadalafil, and…
Read More
MEDVi’s Meteoric AI-Fueled Ascent Faces Scrutiny Amidst FDA Warnings, Allegations of Deceptive Marketing, and Multiple Lawsuits
A telehealth startup, MEDVi, recently lauded by The New York Times as a prime example of an AI-driven billion-dollar enterprise,…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
The digital health company MEDVi, recently spotlighted in an April 2 New York Times profile that depicted CEO Matthew Gallagher…
Read More
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric Growth
In an era increasingly shaped by the transformative power of artificial intelligence, a Los Angeles-based telehealth startup, MEDVi, has captured…
Read More
